The strongest growth in many years, perhaps ever. This is how CEO at Novo Nordisk Lars Fruergaard Jørgensen describes his firm's current advancements in an interview with Danish business daily Børsen.
Precisely growth is highly prioritized, the CEO admits freely.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.